Quentin BarraudExpertise
Translational neuroscience · Neuromodulation · Spinal cord injury & Parkinson’s disease · Multi-omics (single-cell, spatial transcriptomics, 3D cleared-tissue imaging) · Preclinical platform management
Mission
To develop, coordinate, and supervise the preclinical activities of .NeuroRestore at EPFL, integrating innovative neuromodulation, gene therapy, and multi-omic strategies. To ensure regulatory compliance of all animal work, support scientific teams in experimental design, and build bridges b
Johan AuwerxJohan Auwerx is Professor at the École Polytechnique Fédérale in Lausanne, Switzerland, where he occupies the Nestle Chair in Energy Metabolism. Dr. Auwerx has been using molecular physiology and systems genetics to understand metabolism in health, aging and disease. Much of his work focused on understanding how diet, exercise and hormones control metabolism through changing the expression of genes by altering the activity of transcription factors and their associated cofactors. His work was instrumental for the development of agonists of nuclear receptors - a particular class of transcription factors - into drugs, which now are used to treat high blood lipid levels, fatty liver, and type 2 diabetes. Dr. Auwerx was amongst the first to recognize that transcriptional cofactors, which fine-tune the activity of transcription factors, act as energy sensors/effectors that influence metabolic homeostasis. His research validated these cofactors as novel targets to treat metabolic diseases, and spurred the clinical use of natural compounds, such as resveratrol, as modulators of these cofactor pathways.
Johan Auwerx was elected as a member of EMBO in 2003 and is the recipient of a dozen of international scientific prizes, including the Danone International Nutrition Award, the Oskar Minkowski Prize, and the Morgagni Gold Medal. His work is highly cited by his peers with a h-factor of over 100. He is an editorial board member of several journals, including Cell Metabolism, Molecular Systems Biology, The EMBO Journal, Journal of Cell Biology, Cell, and Science. Dr. Auwerx co-founded a handful of biotech companies, including Carex, PhytoDia, and most recently Mitobridge, and has served on several scientific advisory boards.
Dr. Auwerx received both his MD and PhD in Molecular Endocrinology at the Katholieke Universiteit in Leuven, Belgium. He was a post-doctoral research fellow in the Departments of Medicine and Genetics of the University of Washington in Seattle.
Stewart ColeProfessor Stewart Cole is an international authority in bacterial molecular-genetics and genomics. He has made outstanding contributions in several fields including: bacterial anaerobic electron transport; genome analysis of retroviruses and papillomaviruses; antibiotic resistance mechanisms; and the molecular microbiology of toxigenic clostridia. His studies on isoniazid and multidrug resistance in Mycobacterium tuberculosis, together with his pioneering work on the pathogenicity, evolution and genomics of the tubercle and leprosy bacilli, have made him an undisputed leader in the field of mycobacterial research. The findings of his research are of direct relevance to public health and disease-control in both the developing world and the industrialised nations. He has published over 250 scientific papers and review articles, and holds many patents.
Nicolas Jean Philippe GuexTeaching & PhD Courses Bioinformatic Analysis of RNA-sequencing (Fall) BIO-693(a) Bioinformatic Analysis of RNA-sequencing (Spring) BIO-693(b) This course will take place at EPFL in June 2026, from 8th to 12th, in room AAC 137.It introduces the workflows and techniques that are used for the analysis of bulk and single-cell RNA-seq data. It empowers students to understand and analyze their own data. Methods: omics in biomedical research BIOENG-519 High-throughp
Miguel GarciaTeaching & PhD Courses Methods: omics in biomedical research BIOENG-519 High-throughput methodologies broadly called Omics allow to characterize the complexity and dynamics of any biological system. This course will provide a general description of different methods related to the Omics field followed by hands-on rotations in participating technological platforms.
Viktor VorobevEducation BSc | 2017 – 2021 Moscow State University MSc | 2021 – 2023 Skoltech (Skolkovo Institute of Science and Technology)
Solomzi MakohlisoTeaching & PhD Courses Development engineering ENV-470 This course teaches the fundamentals of technologies for development (Development Engineering) to design, pilot, and deploy appropriate, affordable and robust technologies to address sustainable development challenges and especially those related to extreme poverty in Low-income settings. Science, Technology & Vulnerability HUM-287 This course explores how science and technology can address extreme vulnerability caused by
Klaus Benedikt SchönenbergerVision: Scientific research and technology development can be mobilized to help the poorest and most vulnerable in this world. Klaus Schönenberger obtained an MSc in Microengineering (1993), followed by a PhD (1996) from the Swiss Federal Institute of Technology in Lausanne (EPFL). After a post-doc at Lawrence Livermore National Laboratory in California, he spent over 10 years in the medical devices industry in leading positions such as Vice-President of Worldwide R&D in a 100mcompanyandGlobalVice−ResidentofResearchandTechnologyina1bn company. In 2009, as he was working for a medical devices company, he received a shock: he realized that there is a huge imbalance in access to medical technology in industrialized versus low and middle-income countries. After a closer look, he discovered that he imbalance’s main cause is a mismatch between existing technologies and business models, with those needed in low and middle-income countries. He decided to leave industry and, in 2009, he co-founded the EssentialMed Foundation, an innovative non-profit venture. In 2011, realizing that both technology and business models needed a profound rethinking, he joined EPFL where he launched EssentialTech, an initiative inspired by the philosophy of EssentialMed but expanded to a much wider portfolio of "essential" technologies. The university-wide program aims to develop innovative technologies and business models, for the benefit of sustainable development in low and middle-income countries. In this role, he has already launched and overseen a dozen large projects. Major Humanitarian actors such as the ICRC, MSF and Terre des Hommes took notice of the innovative approach proposed, and decided to collaborate in 2015-2016. This has resulted notably in the joint creation between EPFL and ICRC, of the Humanitarian Tech Hub at EPFL. In May 2017, Klaus directed and launched a MOOC(Massive Open Online Course) entitled “Technology Innovation for Sustainable Development” which aims to spread the unique methodology and approach worldwide. As of today, more than 6000 people have enrolled. In 2018 a first spin-off company was created. Award winning Pristem SA will deploy an innovative new digital xray imaging system, specifically designed for low-income contexts. In December 2018, the creation of the EssentialTech centre was announced by EPFL's presidency, and Klaus is now the Centre's director. Another spin-off of the EssentialTech Centre is the company HMCare, launched in 2020, which is deploying a transparent surgical mask. Ute KochExpertise
SCIENTIFIC EXPERTISESCurrent Molecular Biology and Cloning, Developmental Biology, Cellular and Molecular Immunology, Lymphocyte Maturation and Lineage Commitment, Thymic Selection, Hematopoietic Stem Cell Biology, Bone Marrow Transplantation, Graft-versus-Host Disease, Skin Transplantation, T Lymphocyte Subset Induction (Th1 - Th2, Cytokine Regulation), Extensive Knowledge in Flow CytometryIT SKILLSMicrosoft-Office: Word, Excel, PowerPoint.File Maker Pro: Database design and management.Flow cytom
Georges WagnièresGeorges Wagnières received his diploma degree (MSc) in physics from the University of Lausanne, Switzerland, in 1986. He obtained his doctorate in science (PhD) in physics (Biomedical optics) from the Swiss Federal Institute of Technology at Lausanne (EPFL) in 1992 and did a postdoctoral work in the Wellman Laboratories of Photomedicine (Harvard Medical School), Boston, USA, from 1993 to 1994. He also obtained a Master degree in Management of Technology delivered by the Ecole des Hautes Etudes Commerciales (HEC) of Lausanne University and the EPFL in 2001. Georges Wagnières manages a research group active in the fields of: - Detection of early superficial cancers by fluorescence imaging. - Characterization of early superficial cancers by high magnification narrow band imaging. - In vivo and in vitro measurement of the vascular and tissular oxygen concentration by time-resolved luminescence spectroscopy and imaging. - Preclinical and clinical study of new photosensitizers for photodynamic therapy (PDT). - Treatment of neurodegenerative conditions (Alzheimer, Parkinson's diseases) by photobiomodulation. - Preclinical and clinical photodynamic therapy of inflammatory bowel diseases and atheroscerotic plaque. - Improvement of the selective vascular extravasation of chemotherapeutic agents by PDT. - Monitoring the light dosimetry during PDT by fluorescence spectroscopy and imaging. - Monitoring laser treatments of the retina by reflectance imaging. - Light dosimetry and tissue optical spectroscopy. - Radiometry. - Development of light delivery systems for biomedical applications. Georges Wagnières is also co-founder and was chairman of one spin-off companies: - Medlight SA, founded in July 1997, which develops, produces and commercializes light distributors for photodynamic therapy. Georges Wagnières has currently authored more than 235 papers (more than 150 in international journals with review board) and is inventor of 18 patents. He supervised 12 PhD students up to now, and currently teaches biomedical optics and photomedicine in master programs and doctoral schools. In addition, he gives the course entitled "Physique Générale I" to biology first year students registered to the Biology School of the Lausanne's University. MAIN PUBLICATIONS Please visit: https://www.epfl.ch/labs/lifmet/wagnieres/publications/ Rolf GruetterAwards:
1999 Young Investigator Award Plenary Lectureship
, International Society for Neurochemistry
2011 Fellow
, ESMRMB
2011 Teaching Award
, Section Sciences de la Vie, EPFL
Cristina Ramona Cudalbu MoldovanCristina Cudalbu obtained her Bachelors of Science degree in Medical Physics in 2002 and Masters of Science degree in Biophysics and Medical Physics in 2003, both from University Babes-Bolyai, Cluj-Napoca, Romania. In 2006 she obtained her PhD degree in Localized Proton MRS and time domain quantification of cerebral metabolites at 7T and 4.7T at University Lyon 1, RMN Laboratory, Villeurbanne, France.In 2007, she joined, as a Scientist, the Laboratory for Functional and Metabolic Imaging at EPFL, where she implemented new acquisition and quantification techniques for in vivo nitrogen, proton and carbon MRS for preclinical studies. Starting 2012, Cristina Cudalbu was appointed as Research Staff Scientist and 9.4T MRI Operational Manager at Centre d’Imagerie Biomédicale (CIBM) at EPFL. She is now developing new research lines at CIBM, being oriented towards new acquisition and quantification techniques for in vivo proton, phosphorous, carbon, nitrogen MRS and fast MRSI, diffusion weighted spectroscopy and brain macromolecules quantification. She is now applying these developments on chronic hepatic encephalopathy, a research area that she developed at CIBM (https://actu.epfl.ch/news/when-liver-disease-affects-the-brain/), and on different collaborative projects with researchers from the five partner institutions of CIBM. Bruno Emanuel Ferreira De Sousa CorreiaThroughout my PhD and postdoctoral studies I was trained in world-renowned laboratories and institutions in the United States of America (University of Washington and The Scripps Research Institute). Very early in my scientific career I found out my fascination about protein structure and function. My PhD studies evolved in the direction of immunogen design and vaccine engineering which sparked my interest in the many needs and opportunities in vaccinology and translational research. My efforts resulted in an enlightening piece of work where for the first time, computationally designed immunogens elicited potent neutralizing antibodies. During my postdoctoral studies I joined a chemical biology laboratory at the Scripps Research Institute. In this stage I developed novel chemoproteomics methods for the identification of protein-small molecule interaction sites in complex proteomes. In March 2015, I joined the École Polytechnique Fédérale de Lausanne (EPFL) – Switzerland as a tenure track assistant professor. The focus of my research group is to develop computational tools for protein design with particular emphasis in applying these strategies to immunoengineering (e.g. vaccine and cancer immunotherapy). The activities in my laboratory focus on computational design methods development and experimental characterization of the designed proteins. Our laboratory has been awarded with 2 prestigious research grants from the European Research Council. Lastly, I have been awarded the prize for best teacher of Life sciences in 2019.
